I have reading in other groups about various pros and cons
in the use of alpha-1-interferon. One objection is its
toxicity when used IV and in high doses. I wish to bring
virology readers attention to the development of a low-dose
form that is administered by sublingual, mucosal absorption.
It was developed by Dr. D. Koeche in Kenya and by Dr. Joseph
Cummins (DVM) of Amarillo Cell Culture in Texas.
The theory behind administering the drug this way is that
high levels of a-1-interferon are found naturally in the
mucosal secretions of the oral and nasal cavities. If this
is a place where a-1-ifn expresses itself, then maybe its a
place where supplemental a-1-ifn should be administered.
signed: Goblin
pp000165 at interramp.com
